SOAT1 and pancreatic neoplasm: Recent studies have found that the use of the SOAT1 inhibitor AvasimiBE can inhibit the proliferation and migration of HCC cells, and high levels of SOAT1 expression have previously been shown to be associated with a poor prognosis in prostate and pancreatic cancer [92].